Estimating scenarios for survival time in men starting systemic therapies for castration-resistant prostate cancer: A systematic review of randomised trials

2014 ◽  
Vol 50 (11) ◽  
pp. 1916-1924 ◽  
Author(s):  
T.A. West ◽  
B.E. Kiely ◽  
M.R. Stockler
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Survival Time ◽  
Castration Resistant Prostate Cancer ◽  
Randomised Trials ◽  
Castration Resistant ◽  
Systemic Therapies

scholarly journals Impact of new systemic therapies in overall survival in non-metastatic castration resistant prostate cancer: systematic review and meta-analysis

2021 ◽  
Author(s):  
Alejo Rodriguez-Vida ◽  
Andrés Rodríguez-Alonso ◽  
Eduardo Useros-Rodríguez ◽  
Fernando Lopez-Campos ◽  
Oscar Amor-Carro ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Overall Survival ◽  
Meta Analysis ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Systemic Therapies

225 Ac‐PSMA‐617‐targeted alpha therapy for the treatment of metastatic castration‐resistant prostate cancer: A systematic review and meta‐analysis

The Prostate ◽  
2021 ◽  
Author(s):  
Sanjana Ballal ◽  
Madhav P. Yadav ◽  
Ranjit K. Sahoo ◽  
Madhavi Tripathi ◽  
Sada N. Dwivedi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Meta Analysis ◽  
Castration Resistant Prostate Cancer ◽  
Targeted Alpha Therapy ◽  
Castration Resistant ◽  
Alpha Therapy

scholarly journals Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review

PLoS ONE ◽  
2018 ◽  
Vol 13 (12) ◽  
pp. e0208063 ◽  
Author(s):  
Thomas Grochtdreis ◽  
Hans-Helmut König ◽  
Alexander Dobruschkin ◽  
Gunhild von Amsberg ◽  
Judith Dams
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Cost Effectiveness ◽  
Castration Resistant Prostate Cancer ◽  
Cost Analyses ◽  
Castration Resistant

scholarly journals Economic Evaluations of Cabazitaxel for Treatment of Post-docetaxel Metastatic Castration-resistant Prostate Cancer: Evidence from a Systematic Review

2019 ◽  
pp. 1-8
Author(s):  
Nikinaz Ashrafi Shahmirzadi ◽  
Pardis Zaboli ◽  
Monireh Afzali ◽  
Bereket Molla Tigabu ◽  
Mirhamed Hajimiri ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Cost Effective ◽  
Bibliographic Databases ◽  
Economic Evaluations ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Radium 223 ◽  
Number Of Patients ◽  
Effective Option

Background and Objectives: Prostate cancer is an ever-increasing global incidence and has become the fifth leading cause of cancer-related mortality in men. A significant number of patients with prostate cancer develop metastatic castration-resistant prostate cancer (mCRPC). There are a few second-line treatment options for patients with post-docetaxel mCRPC. This systematic review aimed to assess the cost-effectiveness of cabazitaxel for the treatment of mCRPC. Materials and Methods: Electronic bibliographic databases including: PubMed/Medline, NICE, CRD, and Scopus were searched in January 2018 for identifying full economic evaluations published in English and Persian. The risk of assessment bias and descriptive analyses of individual studies’ findings were presented. Results: Three articles that fulfilled the inclusion criteria were included in the current study. All the included records had a reasonable quality. Cabazitaxel was not recommended as the most cost-effective option for the treatment of docetaxel-refractory mCRPC. Abiraterone acetate and radium-223 were the recommended cost-effective treatments for mCRPC treatment. Conclusion: We found that, in general, while cabazitaxel had equal or slightly higher improvement in Quality-adjusted Life Year (QALY) as compared to the alternatives, it incurred a high cost. Despite the inclusion of a few studies in this review, cabazitaxel was not found to be a cost-effective option. Therefore, we recommend full economic evaluations to be conducted in this area.

Development of a prognostic model for survival time prediction in castration-resistant prostate cancer patients

2020 ◽  
Vol 38 (6) ◽  
pp. 600.e9-600.e15
Author(s):  
Judith Stangl-Kremser ◽  
Andrea Mari ◽  
Rodrigo Suarez-Ibarrola ◽  
David D'Andrea ◽  
Stephan M. Korn ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Survival Time ◽  
Cancer Patients ◽  
Prognostic Model ◽  
Castration Resistant Prostate Cancer ◽  
Time Prediction ◽  
Castration Resistant

scholarly journals Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: a systematic review

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Shengri Tian ◽  
Zhen Lei ◽  
Zuo Gong ◽  
Zhonghai Sun ◽  
Dongyuan Xu ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Clinical Implication ◽  
Predictive Biomarkers ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

scholarly journals Quality of docetaxel toxicity reporting for castration resistant prostate cancer (CRPC): A systematic review

2018 ◽  
Vol 29 ◽  
pp. viii297
Author(s):  
S. Cheng ◽  
M. Qureshi ◽  
V. Arciero ◽  
K.K.-W. Chan ◽  
U. Emmenegger
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant
Sign in / Sign up

Export Citation Format

Share Document